| __timestamp | Amphastar Pharmaceuticals, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 660772000 |
| Thursday, January 1, 2015 | 46974000 | 736435000 |
| Friday, January 1, 2016 | 47298000 | 775266000 |
| Sunday, January 1, 2017 | 50918000 | 860348000 |
| Monday, January 1, 2018 | 58044000 | 814775000 |
| Tuesday, January 1, 2019 | 63109000 | 942821000 |
| Wednesday, January 1, 2020 | 65157000 | 985616000 |
| Friday, January 1, 2021 | 68920000 | 1061508000 |
| Saturday, January 1, 2022 | 66592000 | 1190423000 |
| Sunday, January 1, 2023 | 80393000 | 1254234000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Grifols consistently outspent Amphastar, with SG&A expenses peaking at approximately 1.25 billion in 2023, a 90% increase from 2014. In contrast, Amphastar's expenses grew by about 99%, reaching 80 million in 2023. This disparity highlights Grifols' aggressive investment in administrative and sales functions, potentially driving its market dominance. Meanwhile, Amphastar's leaner approach may reflect a focus on operational efficiency. As the industry evolves, these financial strategies will play a pivotal role in shaping the competitive dynamics between these two pharmaceutical giants.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Cost Insights: Breaking Down Grifols, S.A. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE